SOURCE: NanoInk, Inc.

October 16, 2006 10:42 ET

NanoInk CEO to Speak at Lux Executive Summit on Commercializing Nanotechnology

Dr. Cedric Loiret-Bernal Will Discuss NanoInk's Innovative Solutions to Fight Counterfeiting and Illegal Diversion of Blockbuster Pharmaceutical Products

SKOKIE, IL -- (MARKET WIRE) -- October 16, 2006 -- NanoInk, Inc., an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the life science and semiconductor industries, announced today that its Chief Executive Officer, Dr. Cedric Loiret-Bernal, will be a featured guest speaker at the Lux Executive Summit on commercializing nanotechnology.

Held in Cambridge, Mass. at The Charles Hotel on October 16 - 17, 2006, the Lux Executive Summit brings together leaders and innovators in the field of nanotechnology. The conference caters exclusively to senior executives, fund managers and public sector leaders who are leading their industries in emerging technology, while focusing on the business and finance issues of commercialization. More information can be found at www.luxexecutivesummit.com.

Dr. Loiret-Bernal's presentation at 3:30 p.m. Eastern on Tuesday, October 17 will introduce NanoInk's Dip Pen Nanolithography® (DPN®) and Nanoencryption™ technologies.

"We're excited to have NanoInk present at the Lux Executive Summit," said Lux Research CEO Peter Hebert. "The company's unique and innovative technology will resonate with our senior-level attendees."

"Nanotechnology will completely redefine brand protection for the pharmaceutical industry," said Dr. Loiret-Bernal. "My presentation will provide Lux Executive Summit attendees with a closer look at the innovative solutions NanoInk is providing its pharmaceutical customers to fight counterfeiting and illegal diversion of blockbuster pharmaceutical products."

About NanoInk

NanoInk, Inc. is an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the life science and semiconductor industries. With DPN, a patented and proprietary nanofabrication technology that allows for unmatched flexibility and accuracy, and also its high-resolution Nanoencryption technology, NanoInk is able to offer its pharmaceutical customers innovative solutions to fight counterfeiting and illegal diversion of blockbuster pharmaceutical products. Other key applications include nanoscale additive repair and nanoscale rapid prototyping. Located in the new Illinois Science + Technology Park, north of Chicago, NanoInk currently has over 100 issued or pending patents and patent applications filed worldwide and has licensing agreements with Northwestern University, Stanford University, and the University of Illinois at Urbana-Champaign and the Georgia Institute of Technology. For more information on products and services offered by NanoInk, Inc., see www.nanoink.net.

Contact Information